Evidence map›Paper›PMID 36701614›Full record

ArticleObstetrics and gynecology2023

Association of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection With Maternal Mortality and Neonatal Birth Outcomes in Botswana by Human Immunodeficiency Virus Status.

Maya Jackson-Gibson, Modiegi Diseko, Ellen C Caniglia, Gloria K Mayondi, Judith Mabuta, Rebecca Luckett, Sikhulile Moyo, Pamela Lawrence, Mogomotsi Matshaba, Mosepele Mosepele and 6 more

Open access · greenAbstract read
In one paragraph

Article in Obstetrics and gynecology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Maya Jackson-GibsonThe Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; the Botswana Harvard AIDS Institute Partnership, the Department of Internal Medicine, University of Botswana, the Ministry of Health and Wellness, and the Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone, Botswana; and the Department of Obstetrics and Gynecology and the Division of Infectious Diseases, Beth Israel Deaconess Medical Center, the Division of Infectious Diseases, Brigham and Women's Hospital, and the Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Modiegi Diseko
Ellen C Caniglia
Gloria K Mayondi
Judith Mabuta
Rebecca Luckett
Sikhulile Moyo
Pamela Lawrence
Mogomotsi Matshaba
Mosepele Mosepele
Mompati Mmalane
Jaspreet Banga
Shahin Lockman
Joseph Makhema
Rebecca Zash
Roger L Shapiro
Botswana Harvard AIDS Institute Partnership · BW

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
Botswana Birth Outcomes Surveillance ExtensionR01HD095766 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2018 to 2022
$3.3M
Birth Outcomes Surveillance in BotswanaR01HD080471 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2014 to 2018
$2.6M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
Evaluation of triage strategies and screening intervals in a human papillomavirus based cervical cancer screening program in women living with human immunodeficiency virus in BotswanaK08CA271949 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Rebecca Luckett · 2022 to 2026
$1.3M
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral TherapyK23HD088230 · NICHD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZASH, REBECCA MARIE · 2017 to 2021
$820k
Iron and folic acid supplementation strategies during pregnancy and adverse pregnancy outcomes in Botswana - Resubmission - 1K01HD100222 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI CANIGLIA, ELLEN CHRISTINA · 2020 to 2024
$632k
FIC NIH HHS D43 TW010543NCI NIH HHS K08 CA271949NIAID NIH HHS K24 AI131924NIAID NIH HHS T32 AI007387NICHD NIH HHS K01 HD100222NICHD NIH HHS K23 HD088230NICHD NIH HHS R01 HD080471NICHD NIH HHS R01 HD095766
6 · The paper itself

Abstract

objectiveTo evaluate the combined association of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human immunodeficiency virus (HIV) infection on adverse birth outcomes in an HIV-endemic region.

methodsThe Tsepamo Study abstracts data from antenatal and obstetric records in government maternity wards across Botswana. We assessed maternal mortality and adverse birth outcomes for all singleton pregnancies from September 2020 to mid-November 2021 at 13 Tsepamo sites among individuals with documented SARS-CoV-2 screening tests and known HIV status.

resultsOf 20,410 individuals who gave birth, 11,483 (56.3%) were screened for SARS-CoV-2 infection; 4.7% tested positive. People living with HIV were more likely to test positive (144/2,421, 5.9%) than those without HIV (392/9,030, 4.3%) (P=.001). Maternal deaths occurred in 3.7% of those who had a positive SARS-CoV-2 test result compared with 0.1% of those who tested negative (adjusted relative risk [aRR] 31.6, 95% CI 15.4-64.7). Maternal mortality did not differ by HIV status. The offspring of individuals with SARS-CoV-2 infection experienced more overall adverse birth outcomes (34.5% vs 26.6%; aRR 1.2, 95% CI 1.1-1.4), severe adverse birth outcomes (13.6% vs 9.8%; aRR 1.2, 95% CI 1.0-1.5), preterm delivery (21.4% vs 13.4%; aRR 1.4, 95% CI 1.2-1.7), and stillbirth (5.6% vs 2.7%; aRR 1.7 95% CI 1.2-2.5). Neonates exposed to SARS-CoV-2 and HIV infection had the highest prevalence of adverse birth outcomes (43.1% vs 22.6%; aRR 1.7, 95% CI 1.4-2.0).

conclusionInfection with SARS-CoV-2 at the time of delivery was associated with 3.7% maternal mortality and 5.6% stillbirth in Botswana. Most adverse birth outcomes were worse among neonates exposed to both SARS-CoV-2 and HIV infection.

Indexed as

COVID-19HIV InfectionsPregnancy ComplicationsPregnancy Complications, InfectiousPremature BirthBotswanaFemaleHIVHumansInfant, NewbornMaternal MortalityPregnancyPregnancy OutcomeSARS-CoV-2Stillbirth

Identifiers

PMID36701614
PMCPMC10462386
OpenAlexW4311897994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.